5440672025-10-012025-12-315440672025-04-012025-12-315440672025-10-012025-12-31in-capmkt:OtherExpenses1Member5440672025-10-012025-12-31in-capmkt:OtherExpenses2Member5440672025-10-012025-12-31in-capmkt:OtherExpenses3Member5440672025-10-012025-12-31in-capmkt:OtherExpenses4Member5440672025-10-012025-12-31in-capmkt:OtherExpenses5Member5440672025-10-012025-12-31in-capmkt:OtherExpenses6Member5440672025-10-012025-12-31in-capmkt:OtherExpenses7Member5440672025-10-012025-12-31in-capmkt:OtherExpenses8Member5440672025-10-012025-12-31in-capmkt:OtherExpenses9Member5440672025-10-012025-12-31in-capmkt:OtherExpenses10Member5440672025-04-012025-12-31in-capmkt:OtherExpenses1Member5440672025-04-012025-12-31in-capmkt:OtherExpenses2Member5440672025-04-012025-12-31in-capmkt:OtherExpenses3Member5440672025-04-012025-12-31in-capmkt:OtherExpenses4Member5440672025-04-012025-12-31in-capmkt:OtherExpenses5Member5440672025-04-012025-12-31in-capmkt:OtherExpenses6Member5440672025-04-012025-12-31in-capmkt:OtherExpenses7Member5440672025-04-012025-12-31in-capmkt:OtherExpenses8Member5440672025-04-012025-12-31in-capmkt:OtherExpenses9Member5440672025-04-012025-12-31in-capmkt:OtherExpenses10Member5440672025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15440672025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25440672025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15440672025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares544067INNOVACAPNOTLISTEDINE0DUT01020INNOVA CAPTAB LIMITEDMain BoardEquity2025-04-012026-03-312026-01-232026-01-16INRMillionsQuarterlyThird quarterSingle segmentDrugs and Pharmaceutical products2026-01-2312:00:002026-01-2312:45:00Not applicable2025-10-012025-12-31UnauditedConsolidated45029300001654000045194700002808370000150570000-40770000437840000395000001142400004529500003962700000556770000055677000093930000413500001352800000421490000000042149000061900004276800000000572250000107.377.37007.377.371The above consolidated financial results of Innova Captab Limited have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations 2015 Listing Regulation as amended The results for the quarter and nine months ended 31 December 2025 are available on the Company website under investor information section and on the stock exchange website <BR> <BR> 2The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 23 January 2026 the Board of Directors at their meeting held on 23 January 2026 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the standalone financial results for the quarter and period ended 31 December 2025 <BR> <BR> 3The Group comprise the following entities all of which have been incorporated in India <BR> Innova Captab Limited Holding Company <BR> Univentis Medicare Limited Subsidiary Company <BR> Sharon Bio-Medicine Limited Subsidiary Company <BR> Univentis Foundation Subsidiary <BR> <BR> 4The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Code viz Code on wages 2019 Code on Social Security 2020 Industrial Relation Code 2020 and Occupational Safety Health and Working Condition Code 2020 collectively referred to as the New Labour Codes These Codes have been made effective from 21 November 2025 The group is in the process of evaluating the full impact of these new labour codes announced The group has estimated and accounted liability related to gratuity and leave encashment in the standalone financial results <BR> <BR> The Group continues to monitor developments on the rules to be notified by regulatory authorities including clarifications additional guidance from authorities and will continue to assess the accounting implications basis such developments guidance <BR> <BR> 5The Board of Directors of the Holding Company at their meeting held on 23 January 2026 has approved an interim dividend of Rs 2 per equity share face value of Rs 10 per share2025-04-012025-12-31UnauditedConsolidated1182216000058560000118807200007442260000257510000-138390000124589000012305000033791000012366000001050483000013758900000137589000021177000013578000034755000001028340000000010283400001620000102996000000005722500001017.9717.970017.9717.97Power and fuel95460000Stores and spares consumed52090000Packing charges57340000Repairs and maintenance33720000Travelling and conveyance32810000Commission on sales29060000Freight charges34760000Rates, fees and taxes16170000House keeping expense14700000Miscellaneous expenses86840000Power and fuel292990000Stores and spares consumed144320000Packing charges144180000Repairs and maintenance97110000Travelling and conveyance96180000Commission on sales83140000Freight charges78280000Rates, fees and taxes45110000House keeping expense44860000Miscellaneous expenses2104300001The Group has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the groupRemeasurement of defined benefit obligation8360000Income tax relating to items that will not be reclassified to profit or loss-21700006190000Remeasurement of defined benefit obligation2240000Income tax relating to items that will not be reclassified to profit or loss-6200001620000000061900001620000